Kenalog has 28 known drug interactions based on U.S. FDA drug labeling data. 15 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aminoglutethimide, Amphotericin B, Anticholinesterase Agents. Patients taking Kenalog should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 28
- Major
- 15
- Moderate
- 12
Major (15)
- Kenalog + Aminoglutethimide— Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.
- Kenalog + Amphotericin B— Concomitant use with corticosteroids can cause hypokalemia and has been associated with cardiac enlargement and congesti…
- Kenalog + Anticholinesterase Agents— Concomitant use with corticosteroids may produce severe weakness in patients with myasthenia gravis.
- Kenalog + Atazanavir— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Clarithromycin— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Cobicistat— Strong CYP3A4 inhibitor (in cobicistat-containing products) may cause increased plasma concentration of triamcinolone ac…
- Kenalog + Cyclosporine— Increased activity of both cyclosporine and corticosteroids may occur concurrently, with reports of convulsions.
- Kenalog + Indinavir— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Itraconazole— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Ketoconazole— Decreases metabolism of triamcinolone acetonide by up to 60%, increasing risk of corticosteroid side effects.
- Kenalog + Nefazodone— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Nelfinavir— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Ritonavir— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Saquinavir— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
- Kenalog + Telithromycin— Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.
Moderate (12)
- Kenalog + Acidifying Agents— Corticosteroids may increase blood glucose concentrations; dosage adjustments may be required.
- Kenalog + Barbiturates— Hepatic enzyme inducers may increase corticosteroid metabolism and reduce efficacy.
- Kenalog + Carbamazepine— Hepatic enzyme inducer may increase corticosteroid metabolism and reduce efficacy.
- Kenalog + Cholestyramine Light— Cholestyramine may increase the clearance of corticosteroids.
- Kenalog + Digitalis Glycosides— Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia caused by corticosteroids.
- Kenalog + Estrogens— Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.
- Kenalog + Isoniazid— Serum concentrations of isoniazid may be decreased by corticosteroids.
- Kenalog + Macrolide Antibiotics— Macrolide antibiotics cause a significant decrease in corticosteroid clearance.
- Kenalog + Oral Contraceptives— Estrogens in oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.
- Kenalog + Phenytoin— Hepatic enzyme inducer may increase corticosteroid metabolism and reduce efficacy.
- Kenalog + Rifampin— Hepatic enzyme inducer may increase corticosteroid metabolism and reduce efficacy.
- Kenalog + Warfarin— Co-administration usually results in inhibition of warfarin response; coagulation indices should be monitored frequently…